KR20240012413A - 폐암 치료를 위한 조성물 및 방법 - Google Patents

폐암 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240012413A
KR20240012413A KR1020237041378A KR20237041378A KR20240012413A KR 20240012413 A KR20240012413 A KR 20240012413A KR 1020237041378 A KR1020237041378 A KR 1020237041378A KR 20237041378 A KR20237041378 A KR 20237041378A KR 20240012413 A KR20240012413 A KR 20240012413A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
acid sequence
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041378A
Other languages
English (en)
Korean (ko)
Inventor
3세 앤서니 야르코프스키
필립 데니스
레오 트라니
마이클 뉴턴
노라 샤이어
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240012413A publication Critical patent/KR20240012413A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237041378A 2021-05-24 2022-05-24 폐암 치료를 위한 조성물 및 방법 Pending KR20240012413A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192217P 2021-05-24 2021-05-24
US63/192,217 2021-05-24
PCT/EP2022/064061 WO2022248478A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Publications (1)

Publication Number Publication Date
KR20240012413A true KR20240012413A (ko) 2024-01-29

Family

ID=82100132

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041378A Pending KR20240012413A (ko) 2021-05-24 2022-05-24 폐암 치료를 위한 조성물 및 방법

Country Status (11)

Country Link
US (1) US20240254235A1 (https=)
EP (1) EP4347038A1 (https=)
JP (1) JP2024521105A (https=)
KR (1) KR20240012413A (https=)
CN (1) CN117425493A (https=)
AU (1) AU2022281992A1 (https=)
BR (1) BR112023023833A2 (https=)
CA (1) CA3219960A1 (https=)
IL (1) IL308530A (https=)
TW (1) TW202313107A (https=)
WO (1) WO2022248478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936347A (zh) * 2023-04-14 2025-11-11 阿斯利康(瑞典)有限公司 非小细胞肺癌的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US20190276543A1 (en) * 2018-03-08 2019-09-12 Astrazeneca Pharmaceuticals Lp Compositions and methods for treating late stage lung cancer
BR112022022304A2 (pt) * 2020-05-04 2022-12-20 Merck Sharp & Dohme Llc Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp

Also Published As

Publication number Publication date
IL308530A (en) 2024-01-01
JP2024521105A (ja) 2024-05-28
AU2022281992A1 (en) 2024-01-04
EP4347038A1 (en) 2024-04-10
WO2022248478A1 (en) 2022-12-01
US20240254235A1 (en) 2024-08-01
BR112023023833A2 (pt) 2024-01-30
CA3219960A1 (en) 2022-12-01
TW202313107A (zh) 2023-04-01
CN117425493A (zh) 2024-01-19

Similar Documents

Publication Publication Date Title
US20230013642A1 (en) Toxicity Management for Anti-Tumor Activity of CARs
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
JP7654557B2 (ja) Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
JP7807392B2 (ja) 癌をキメラ抗原受容体により処置する組成物及び方法
CA3107938C (en) Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
BR112020014446A2 (pt) Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
JP2024540347A (ja) 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法
KR20240012413A (ko) 폐암 치료를 위한 조성물 및 방법
US20260115284A1 (en) Toxicity management for anti-tumor activity of cars
JP2023103254A (ja) 後期肺癌の処置のための組成物及び方法
HK40069741A (en) Toxicity management for anti-tumor activity of cars
Valia Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia
HK40039113A (en) Toxicity management for anti-tumor activity of cars
EA041322B1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application